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5Abbreviations
AEBSF – aminoethylbenzene sulfonylfluoride 
BMZ – basement membrane zone
BP – bullous pemphigoid
BSA – bovine serum albumin
DEJ – dermal-epidermal junction
EBA – epidermolysis bullosa acquisita
EDTA – ethylenediamine tetraacetic acid
IC – immune complexes
IF – immunofluorescence
LAD – linear IgA disease
LAD-1 – linear IgA disease antigen 1
MoAb – monoclonal antibody
NBT – nitroblue tetrazolium
OCT – optimum cutting temperature
PBS – phosphate buffered saline
PMSF – phenylmethylsulfonyl fluoride
1Introduction
Autoimmune bullous diseases are chronic diseases of unknown origin characterized 
by blistering of the skin and associated with tissue-bound and circulating 
autoantibodies to structural components of the skin. Based on clinical and 
histopathological features, autoimmune bullous diseases may be divided into 
pemphigus-type and subepidermal autoimmune diseases. The first group of 
diseases includes blistering diseases characterized by intraepidermal blister 
formation due to the loss of adhesion of keratinocytes and is associated with 
autoantibodies to the intercellular junctions of keratinocytes. The second group of 
diseases is characterized by subepidermal blisters caused by the loss of attachment 
of basal keratinocytes to the underlying basement membrane and is associated with 
autoantibodies to the dermal-epidermal junction. 
Autoantibodies in patients with pemphigus were shown to specifically react with 
desmogleins (Stanley et al, 1982; Amagai et al, 1991; Karpati et al, 1993; Wang et 
al, 1997) and desmocollins (Hashimoto et al, 1997) (desmosomal transmembrane 
cell-adhesion molecules of cadherin type), with plakoglobin (an intracellular protein of 
the plakin family) (Korman et al, 1989), and with acethylcholine receptors (Nguyen et 
al, 2000a; Nguyen et al, 2000b). 
Over the past two decades, efforts have been made to identify antigens at the 
dermal-epidermal junction (DEJ) recognized by autoantibodies in patients with 
various forms of autoimmune subepidermal blistering diseases (Figure 1). 
Depending on the primary site of involvement, autoantibodies may bind to distinct 
DEJ molecules: the bullous pemphigoid (BP) antigens of 230kD (BP230) (Stanley et 
al, 1981) or 180kD (BP180) (Diaz et al, 1990; Giudice et al, 1992), plectin (Laffitte et 
al, 2001) and the 3 (Domloge-Hultsch et al, 1992; Kirtschig et al, 1995), 3 
(Ghohestani et al, 2000b), and 2 (Nousari et al, 1999) subunits of laminin-5; the 6
(Bhol et al, 2001) and 4 (Tyagi et al, 1996; Bhol et al, 2000; Kumari et al, 2001)
chains of 64 integrin; a 168¯ 170kD mucosal antigen (Ghohestani et al, 1996); a 
200 kDa dermal autoantigen (Zillikens et al, 1996), type VII collagen (Woodley et al,
1984), and the 5 chain of type IV collagen (Ghohestani et al, 2000a). DEJ 
2Figure 1. Schematic representation of autoantigens of the dermal-epidermal junction. 
Structural components of the skin basement membrane that may function as autoantigens in 
subepidermal blistering diseases and their relative position are shown. Plectin and BP230 are 
intracellular hemidesmosomal proteins. BP230 interacts with BP180 and 64 integrin which 
are transmembrane hemidesmosomal components. The 6 chain of 64 integrin interacts 
extracellularly with BP180. 6 4 integrin is a known ligand for laminin 5 in the lower lamina 
lucida and lamina densa. P200 is a not yet fully characterized autoantigen localized to the 
lower lamina lucida. Beside other ubiquitous proteins like perlecan and nidogen (not shown), 
laminin 5 and type IV collagen form a network in the lamina densa. Laminin 5 binds to type 
VII collagen which represents the major component of anchoring fibrils. 
molecules that were identified as autoantigens in subepidermal blistering diseases 
are represented in Figure 1.
Epidermolysis bullosa acquisita (EBA) is a rare chronic blistering disease of skin and 
mucous membranes characterized by subepidermal blisters and tissue-bound and 
circulating autoantibodies to the dermal-epidermal junction (DEJ). Type VII collagen, 
the main constituent of anchoring fibrils, was identified as the autoantigen of EBA 
(Woodley et al, 1984; Woodley et al, 1988). 
3EBA is a clinically heterogeneous disease and patients may present with an 
inflammatory or non-inflammatory phenotype. The first cases of a blistering disease 
with adult onset and features highly reminiscent of hereditary dystrophic 
epidermolysis bullosa were reported by Elliott more than 100 years ago (Elliott 1895). 
The mechanobullous, non-inflammatory form of EBA, was defined in 1971 and is 
characterized by extreme skin fragility, trauma-induced blisters and erosions 
localized to the extensor skin surface, healing with scars and milia (Roenigk et al,
1971). In addition to the mechano-bullous variant, several inflammatory subtypes of 
EBA were described, clinically mimicking bullous pemphigoid, linear IgA disease, or 
mucos membrane pemphigoid (Dahl 1979; Gammon et al, 1982a; Gammon et al,
1984b). Certain EBA patients present with inflammatory phenotype at the onset of 
the disease with overlapping or later evolving mechanobullous features (Gammon et 
al, 1984b; Stewart et al, 1991). EBA typically affects adults but juvenile cases were 
also reported (McCuaig et al, 1989; Bernard et al, 1995; Lacour et al, 1995; Callot-
Mellot et al, 1997; Caux et al, 1997; Park et al, 1997; Schmidt et al, 2002). EBA is a 
rare disease occuring in approximately 5% of unselected patients with basement 
membrane zone antibodies (Zhu et al, 1990). 
The disease is immunopathologically characterized by deposition of 
immunoreactants at the DEJ by direct immunofluorescence (IF) microscopy. The  
IgG and/or C3 deposits were shown to localize to the sublamina densa region of DEJ 
by direct immunoelectron microscopy (Yaoita et al, 1981). Indirect IF microscopy on 
1M NaCl split-skin evidenced autoantibodies to the dermal versant of the DEJ in 
serum of EBA patients (Gammon et al, 1984a) which label the sublamina densa 
zone by indirect immunoelectronmicroscopy (Woodley et al, 1984). Altough the site 
of immunoreactants deposition is always lamina/sublamina densa region, in some 
EBA patients the cleavage plane localizes to the lamina lucida of the DEJ (Fine et al,
1989). EBA serum autoantibodies recognize the 290 kDa type VII collagen by 
immunoblotting with dermal extracts (Woodley et al, 1984) and immunoprecipitation 
with keratinocyte and fibroblast extracts (Stanley et al, 1985). 
Type VII collagen, initially isolated from human chorioamniotic membranes, is an 
anti-parallel dimer recognized as the major constituent of anchoring fibrils (Bentz  et 
al, 1983; Morris et al, 1986; Sakai et al, 1986; Keene et al, 1987). The gene 
4COL7A1, encoding for the human type VII collagen was mapped to the short arm of 
the chromosome 3 (Parente et al, 1991; Greenspan et al, 1993). The COL7A1 gene 
consists of 118 exons, more than any previously described gene (Christiano et al,
1994a). Type VII collagen is composed of three identical  chains, each consisting of 
a 145-kDa central collagenous triple-helical portion, flanked by a large 145-kDa 
amino-terminal non-collagenous domain (NC1), and a smaller 34-Kda carboxy-
terminal non-collagenous domain (NC2) (Parente et al, 1991) (Figure 2). In the 
extracellular space, type VII collagen molecules form antiparallel tail-to-tail dimers 
stabilized by disulfide bonding through a small carboxy-terminal overlap (NC2), while 
a fragment of the NC2 domain is proteolitically removed (Bruckner-Tuderman et al,
1995; Chen et al, 2001). 
The epitopes recognized by EBA sera were mapped to the NC1 domain of type VII 
collagen and autoantibodies in a minority of sera were also shown to react with triple-
helical or NC2 domains (Woodley et al, 1988; Gammon et al, 1993; Lapiere et al,
1993; Tanaka et al, 1994; Chen et al, 2001; Schmidt et al, 2002), while exclusive 
reactivity to the triple-helical domain was documented in only three children with EBA 
(Tanaka et al, 1997).
The biological significance of type VII collagen is further substantiated by the 
existence of a hereditary form of dystrophic epidermolysis bullosa. In the skin of 
these patients type VII collagen shows altered expression. Evidence accumulated 
that genetic defects in the correct synthesis, secretion, or in the molecular assembly 
of type VII collagen cause the different clinical forms of dystrophic epidermolysis 
bullosa (Leigh et al, 1988; Bruckner-Tuderman et al, 1989; Bruckner-Tuderman et al,
1990; Smith and Sybert 1990; Christiano et al, 1993; Christiano et al, 1994b; 
Hovnanian et al, 1997). Interestingly, type VII collagen was found to have an 
elevated and topographically aberrant expression in the dermis of patients with 
systemic sclerosis under the regulatory action of transforming growth factor-beta 
(TGF-). The presence of type VII collagen in the dermis may contribute to the tightly 
bound and indurated appearance of the affected skin in these patients (Rudnicka et 
al, 1994).
EBA is thought to be an antibody-mediated autoimmune disease. It has been 
suggested that EBA autoantibodies may disrupt the interaction of type VII collagen 
5with fibronectin or may interfere with the antiparallel dimer formation (Woodley et al,
1987; Chen et al, 2001). In addition, a pathomechanism of immune complex-
mediated inflammation involving complement and leukocyte activation was proposed 
(Gammon et al, 1984c; Gammon et al, 1989; Mooney et al, 1992). However, there is 
a functional heterogeneity of in situ bound and circulating autoantibodies in EBA with 
respect to their complement-fixing ability and capacity to induce neutrophil 
chemotaxis and activation (Gammon and Briggaman 1987). Subclass distribution of 
polyclonal EBA autoantibodies was also shown not to correlate with their 
complement-fixing ability (Mooney and Gammon 1990; Bernard et al, 1991; Cho et 
al, 1998) nor to the clinical phenotype (Gandhi et al, 2000).
In other autoimmune blistering diseases, including pemphigus and anti-
epiligrin/laminin 5 pemphigoid, the blister-inducing capacity of patients’ 
autoantibodies has been demonstrated by passive transfer into neonatal BALB/c and 
severe combined immunodeficient (SCID) mice, respectively (Anhalt et al, 1982; 
Lazarova et al, 1996). Autoantibodies to 4 chain of 64 integrin from patients with 
ocular cicatricial pemphigoid were shown to induce subepidermal blisters in an in 
vitro conjunctival organ culture model (Chan et al, 1999). In addition, autoantibodies 
to 6 chain of 64 integrin from patients with patients with oral pemphigoid produced 
subepidermal blisters when incubated with cultured normal human buccal mucosa 
(Bhol et al, 2001). While antibodies from patients with bullous pemphigoid do not 
cross-react with murine skin and do not induce blisters by passive transfer into 
neonatal mice, IgG from rabbits, immunized with recombinant murine type XVII 
collagen/BP180, led to a blistering disease in the mice that mimicked bullous 
pemphigoid (Liu et al, 1993). Recently, we demonstrated that autoantibodies to 
human type XVII collagen from patients with bullous pemphigoid induce dermal-
epidermal separation in cryosections of human skin when co-incubated with 
leukocytes from healthy volunteers (Sitaru et al, 2002). However, the blister-inducing 
capacity of autoantibodies to type VII collagen has not yet been unequivocally 
demonstrated. Previous attempts to induce EBA by passive transfer of patients‘ 
autoantibodies into neonatal BALB/c mice (Shigemoto et al, 1988; Borradori et al,
1995) or human skin grafted onto SCID mice were not successful (Chen et al, 1992).
6Aim of the study
The aim of the present study was to demonstrate the blister-inducing ability of 
autoantibodies to type VII collagen from serum of patients with EBA. Previously, sera 
from some EBA patients were shown to induce leukocyte recruitment to the DEJ 
using a leukocyte attachment assay (Gammon et al, 1984c). Modifying this assay, 
we incubated cryosections of human skin with IgG preparations from EBA patients 
and subsequently with leukocytes from healthy donors. We addressed the question, 
if autoantibodies from EBA sera, affinity-purified against recombinant type VII 
collagen, have the ability to trigger an immune complex-mediated inflammation 
leading to blister formation in the cryosections. In further experiments, we aimed at 
defining the epitopes targeted by the pathogenic autoantibodies, the ultrastructural 
site of blister formation, the leukocyte subpopulations that mediate this effect, and 
the role of the Fc portion of autoantibodies for dermal-epidermal separation in this 
model. 
7Materials and Methods
Antibodies 
Serum samples were obtained from 16 patients with EBA prior to the initiation of 
treatment (Table 1). Nine out of the 16 patients presented with the non-inflammatory 
type of the disease and 5 with inflammatory EBA, while in 2 patients, the clinical data 
available did not allow a precise classification. Two patients (EBA13 and EBA14) 
suffered from the childhood variant of the disease (5 and 6 years, respectively), the 
remaining of the patients were adults (mean age 58 years). All EBA patients were 
characterized by 1) blisters on the skin; 2) linear deposits of IgG at the DEJ by direct 
IF microscopy; 3) circulating IgG autoantibodies binding to the dermal side of 1M 
NaCl-split human skin by indirect IF microscopy (titers ranging from 40 to 1280); and 
4) immunoblot reactivity with type VII collagen extracted from dermis. By 
complement-fixation test on neonatal foreskin (Katz et al, 1976), 12 EBA sera fixed 
complement to the dermal-epidermal junction, whereas 4 sera did not. Serum 
samples from patients with bullous pemphigoid (n=20), pemphigus vulgaris (n=6), 
and from healthy donors (n=20) were used as controls. Murine mAbs to type IV 
collagen (clone CIV 22, IgG1) and to type VII collagen (clone LH7.2, IgG1) were 
purchased from Sigma (St. Louis, MO). 
8Table 1. Characteristics of EBA patients included in this study
Patient IIF TiterA CBT (C3)B Type VII CollagenC rNC1D
EBA1 40 - + +
EBA2 160 + + +
EBA3 320 + + +
EBA4 320 + + +
EBA5 160 + + +
EBA6 160 + + +
EBA7 320 + + +
EBA8 160 - + +
EBA9 160 + + +
EBA10 640 + + +
EBA11 160 + + +
EBA12 160 + + +
EBA13 1280 + + +
EBA14 640 - + +
EBA15 80 - + +
EBA16 320 - + +
AAntibody titer by indirect IF microscopy on 1M NaCl-split human skin. BComplement-
fixing capacity as revealed by complement-fixing test on neonatal foreskin. 
CImmunoblot reactivity with full-lenght type VII collagen extracted from dermis. 
DImmunoblot reactivity with the recombinant NC1 domain of type VII collagen.
Construction of cDNA for the Type VII Collagen NC1 Domain 
Amplification and cloning procedures were performed as described previously 
(Kromminga et al, 2000; Kromminga et al, 2002). Briefly, primers for polymerase 
chain reactions (PCR) were synthesized by Perkin-Elmer/Applied Biosystems (Foster 
City, CA). DNA sequence data of type VII collagen were retrieved from EMBL DNA 
9Figure 2. Schematic diagram of type VII collagen. (A) Type VII collagen molecule is a 
homotrimer composed of  chains. After secretion into the extracellular space, type VII 
collagen molecules form tail-to-tail dimers stabilized by disulfide bonding through a carboxy-
terminal overlap. (B) Each  chain is composed of a central triple helical domain flanked by 
a large non-collagenous portion (NC1) at the N-terminus and by a smaller non-collagenous 
domain (NC2) at the C-terminus. The number of base pairs (bp) of the NC1-cDNA fragment 
corresponding to the NC1 domain recombinantly expressed is shown above the bar. 
Recombinant NC1 protein contains a hexahistidine moiety at the N-terminus.
data bank (Cambridge, UK) using the most recent accession number 
NM_000094.(Parente et al, 1991) The full-length 3787 bp NC1-cDNA (nt 114-3878) 
was generated by applying nested PCR on a cDNA pool generated by reverse 
transcription of total RNA from human keratinocytes. Restriction sites for Sal I and 
Hind III were introduced during the nested PCR using the primer pair p323 
gatcaagctt atgacgctgcggcttctggtggccgcgctctg and p326 
gatcgtcgac ctggccctttggacaatacactgggcagggc. The NC1-cDNA was cloned into 
linearized pBBH2c (Invitrogen, Carlsbad, CA) resulting in the recombinant transfer 
vector pBBHNC1-FL. The presence of correct inserts was verified by DNA sequence 
analysis following the dideoxy method using a DyeDideoxy Terminator kit (Perkin 
Elmer) and a 377 DNA sequence analyzer (Perkin Elmer). 
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Figure 3. Expression of the recombinant NC1 domain of type VII collagen in 
baculovirus-infected insect cells. (a) Spodoptera frugiperda (Sf) 21 were co-
transfected with the recombinant vector pBBHNC1-FL and linearized baculovirus 
AcMNPV DNA using the liposome technique. (b) The resulting recombinant baculovirus 
BV-NC1 was purified by plaque assay. A plaque indicates the presence of recombinant 
virus (arrow). (c) The ratio of virus copies to insect cells (i.e., multiplicity of infections, 
MOI) yielding the largest amount of recombinant protein was determined by infecting 2 x 
105 insect cells with different dilutions of high-titer virus stock resulting in MOI of 1, 2, 3, 
and 4, respectively. The insect cell lysates were then analyzed by immunoblotting with 
monoclonal anti-RGSHHH-antibody (e.g., for this experiment a MOI of 2 resulted in best
expression of recombinant NC1). (d) Under these optimized conditions, the expression 
of recombinant NC1 was scaled-up and the recombinant protein was purified from insect 
cell lysates by immobilized metalochelate affinity chromatography using Ni-NTA. The 
eluted fractions (lanes 7-15) were analyzed by SDS-PAGE and protein rich fractions 
were pooled (lanes 9-11). Molecular weight marker is shown in lane 3.
Heterologous Expression of Type VII Collagen NC1 in Sf21 Insect Cells 
Spodoptera frugiperda 21 (Sf21) insect cells (Invitrogen) grown in Grace’s insect 
medium (Invitrogen) were co-transfected with the recombinant vector pBBHNC1-FL 
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and linearized baculovirus AcMNPV DNA (Bac-N-Blue™, Invitrogen) using the 
liposome technique resulting in recombinant baculovirus BV-NC1 (Figure 3). For 
control experiments, insect cells were co-transfected with linear baculovirus DNA and 
transfer vector pBBH2c (lacking NC1-cDNA) resulting in recombinant baculovirus 
BV-0. Recombinant baculovirus clones were identified and purified by plaque assay. 
Recombinant NC1 and a vector-specific peptide of 52 amino acids including only the 
hexa-histidine tag and a sequence encoded by the multi-cloning site, but no NC1 
sequence, were expressed by infecting the cells with recombinant baculovirus BV-
NC1 or BV-0 at a multiplicity of infection of 5.0 and 4.0, respectively. Two days post-
infection, the recombinant hexa-histidine tagged proteins were purified from Sf21 
insect cells by immobilized metal chelate affinity chromatography using Ni-NTA 
agarose (Qiagen). For analysis of expression and purification of the recombinant 
protein, monoclonal anti-RGSHHH-antibody (Qiagen) was used (Kromminga et al,
2002). Protein concentrations were measured by Bradford assay (Biorad, Hercules, 
CA). 
Immunoblot Analysis 
Extracts of human dermis were prepared as described (Zillikens et al, 1996). Briefly 
strips of skin discarded from plastic surgery or alternatively foreskins were incubated 
in phosphate buffered saline (PBS) containing 1 M NaCl, 2 mM EDTA and 2mM 
PMSF for 48 hours at 4°C to separate epidermis and dermis. The epidermis was 
then removed using fine foreceps. Dermal proteins were extracted for 1 hour at room 
temperature using a buffer containing 12.5 mM Tris-HCL, 8 M urea, 0,1 M DL-
Dithiothreitol, 2 mM EDTA 2% w/v SDS and a cocktail of protease inhibitors (all 
Sigma, Deisenhofen, Germany). The extract was centrifuged at 15.000 g for 10 
minutes at 4°C, aliquoted and stored at –80°C until used. Recombinant NC1 or 
dermal extracts were fractionated by 8% and 6% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), respectively, transferred to 
nitrocellulose, and analyzed by immunoblotting (Zillikens et al, 1999). Blots were 
blocked for 45 minutes in 5% solution of skimmed milk powder in Tris-buffered saline 
plus Tween-20 (TBST) buffer (0.02 M Tris-[hydromethyl)-aminomethane, 0.14 M 
NaCl, TWEEN-20 0.01%, pH 7.5, all Sigma). Sera from patients and healthy controls 
were diluted 1:100 and bound autoantibodies were visualized enzymatically using 
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peroxidase-conjugated rabbit anti-human IgG (1:500) (DAKO, Glostrup, Denmark). 
Type VII collagen in dermal extracts and recombinant NC1 were detected by the 
mouse monoclonal antibody LH7.2 (diluted 1:100 in 1% BSA TBST; Sigma). As 
second antibody HRP-conjugated rabbit anti-mouse antibody (1:500, DAKO) was 
used.
Affinity-Purification of Total IgG and IgG Specific for Type VII Collagen
IgG from serum of patients and controls was isolated using Protein G Sepharose 
Fast Flow affinity column chromatography following the instructions of the 
manufacturer (Pharmacia AB, Uppsala, Sweden). Antibodies from sera of EBA 
patients were affinity-purified using an AminoLink Plus immobilization kit following 
the manufacturer‘s instructions (Pierce, Rockford, IL). Recombinant protein encoded 
by BV-0 (lacking NC1) and recombinant NC1 protein (also including the vector-
specific peptide) were covalently coupled to 4% beaded agarose at pH 10 and 
incubated with patient’s serum for 1 hour. Antibodies were eluted with 0.1 M glycine 
buffer (pH 2.5), neutralized with Tris-HCl, and concentrated under extensive washing 
with PBS (pH 7.2) using Ultrafree 15 filters (Millipore, Bradford, MA). Flow-through 
fractions were subjected to Protein G column chromatography and concentrations of 
IgG in flow-through and eluted fractions were determined by absorbance at 280 nm. 
Reactivity of both fractions was analyzed by indirect IF microscopy on salt-split skin 
and by immunoblotting with cell-derived type VII collagen or recombinant NC1. 
Preparation of IgG F(ab’)2 Fragments 
Immunoaffinity purified antibodies specific to type VII collagen were subjected to 
pepsin digestion (Parham 1983). Briefly, antibodies previously purified against 
recombinant NC1 were dialysed against 0.1M acetate buffer (pH 4) at 4°C for 4 
hours. Pepsin in a concentration of 1:20 (pepsin to IgG) was added and the mixture 
was incubated at 37°C for 5 hrs with constant shaking. After the reaction was 
stopped with 50µl/ml 0.2M TRIS, the mixture was dialysed against PBS at 4°C 
overnight. Fc portions and undigested IgG were removed by protein G affinity 
chromatography and the F(ab‘)2 preparation was concentrated by ultrafiltration. 
Completeness of fragmentation and reactivity of the F(ab‘)2 preparations were tested 
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by indirect IF microscopy on 1 M NaCl split-skin using FITC labelled secondary 
antibodies specific to Fab (Sigma, St. Louis, MO) and Fc (Serotec Ltd, Oxford, UK) 
portions of IgG, respectively. 
Peripheral Blood Leukocytes and Complement 
Peripheral blood leukocytes from healthy volunteers were isolated by a 
sedimentation gradient medium containing sodium diatrizoate and dextran 500 
(Nycomed, Oslo, Norway). Cells were harvested, washed twice in RPMI 1640 (Life 
Technologies, Karlsruhe, Germany) and resuspended in the same medium. The cell 
suspension was kept on ice and cell viability was tested using trypan blue; 
preparations with a viability greater than 95% were used. To determine the activation 
status of leukocytes, the cells were resuspended in medium containing 0.05% 
nitroblue tetrazolium (NBT; Roth, Karlsruhe, Germany) prior to incubation with the 
cryosections. Subsequently, unfixed sections were examined by light microscopy for 
the presence of dark blue formazan precipitates. Serum samples from healthy 
volunteers served as a source of human complement and were diluted 2-fold with 
RPMI (Gammon et al, 1980).
Treatment of Cryostat Sections 
Neonatal human foreskin, obtained from routine circumcision, was washed in cold 
PBS, cut in pieces of 5 x 15 mm, embedded in optimum cutting temperature 
compound (Sakura Finetek Europe B.V., Zoeterwonde, Netherland), and stored at    
-80°C. Four cryosections of 6 µm were placed in the center of a Superfrost Plus 
microscope slide (Menzel-Gläser, Braunschweig, Germany). Sera from EBA patients 
and controls were heat-inactivated for 30 minutes at 56°C and diluted 2-fold in PBS. 
Prior to the treatment of skin sections, protein G affinity-purified IgG from EBA sera 
was diluted in PBS to an indirect IF titer of 80 and the monoclonal antibody LH7.2 
was used at an indirect IF titer of 1000. When EBA sera were purified against 
recombinant type VII collagen NC1, flow-through and eluted fractions were adjusted 
to an IgG concentration of 0.5 mg/ml. Skin sections were washed with PBS for 5 
minutes to remove embedding medium before incubation with 50 µl of diluted sera or 
antibody preparations (90 minutes at room temperature). After washing the sections 
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with PBS twice, chambers were prepared as described (Gammon et al, 1982b) and 
the leukocyte suspension, mixed 1:1 with either diluted fresh or heated serum or 
medium alone, was injected into the chambers. Incubation occured in a humidified 
air incubator containing 5% CO2 for 3 hours at 37°C. Subsequently, chambers were 
disassembled, sections were washed in PBS for 10 minutes, air dried for 10 minutes, 
fixed in formaline, and stained with hematoxylin and eosin.
15
Results
Preparation of the Recombinant NC1 Domain of Type VII Collagen 
The recombinant NC1 domain was expressed in insect cells infected with 
baculovirus and purified by immobilized metalochelate affinity chromatography using 
Ni-NTA agarose. Sera from 16 EBA patients and mAb LH7.2 reacted with the 145 
kDa recombinant NC1 domain by immunoblotting, in contrast to sera from patients 
with bullous pemphigoid (n=20), pemphigus vulgaris (n=6), and from healthy controls 
(n=20). Typical patterns of immunoblot reactivity with recombinant NC1 are 
represented in Figure 4.
Figure 4. Sera from patients with EBA, but not control sera, recognize the 
recombinant NC1 domain of type VII collagen by immunoblotting. Like a monoclonal 
antibody to type VII collagen (lane 1), sera from EBA patients (lanes 2-5) strongly reacted 
with recombinant NC1 by immunoblot analysis. In contrast, sera from patients with bullous 
pemphigoid (lanes 6-9), pemphigus vulgaris (lanes 10,11), and healthy controls (lanes 12-
16) show no reactivity with this recombinant protein.
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Sera from EBA Patients Recruit Neutrophils to the Dermal-Epidermal Junction 
and Induce Subepidermal Splits in Cryosections of Human Skin 
Cryosections of normal human skin were incubated with serum samples from EBA 
patients (n=16) and, subsequently, with leukocytes from healthy donors. IgG from 
EBA sera, but not from healthy controls, bound to the DEJ as revealed by indirect IF 
microscopy (Figure 5a). Addition of leukocytes resulted in the recruitment of 
leukocytes to the DEJ in cryosections that had been incubated with EBA sera, but 
not in those incubated with sera from controls (Figure 5b). We usually observed 
more background attachment of leukocytes when the sections were incubated with 
EBA sera compared with sections that were treated with control sera. To investigate 
the time-dependency of neutrophil attachment and blister formation, we incubated 
the cryosections, that had been treated with sera from patients EBA8 and EBA11, 
with leukocytes for 30, 60, 90, 120 and 180 minutes, respectively. Leukocyte 
attachment to the DEJ was strongest after an incubation time of 60 minutes 
(covering 65% of the length of the DEJ) and declined subsequently (30%, 14%, and 
almost no binding at 90, 120, and 180 minutes incubation, respectively). Dermal-
epidermal separation was first seen after an incubation time of 60 minutes (on 10% 
of the length of the DEJ); with longer incubation times, the extent of dermal-
epidermal separation increased and reached its maximum after 120 minutes 
(dermal-epidermal separation on 60% of the length of the DEJ) (Figure 5e). No 
dermal-epidermal separation was seen in cryosections treated with control sera 
(Figure 5f). The extent of dermal-epidermal separation was dependent on the 
number of leukocytes. At a 2 hour incubation, splits were seen when we used 107 
cells/ml. The separation became larger with the use of greater numbers of 
neutrophils. With numbers exceeding 3x107/ml, the extent of splits did not further 
increase, but both epidermis and dermis were non-specifically and increasingly 
damaged. When we used leukocyte numbers below 107/ml or when we omitted 
leukocytes, this abolished blister induction completely. Under the optimized assay 
conditions (incubation with 3x107 leukocytes for 120 minutes), 14 out of 16 EBA sera 
induced dermal-epidermal separation, while serum from EBA13 and EBA14 did not. 
End point titers of immunoblot reactivity with recombinant NC1 of those EBA sera 
that induced a dermal-epidermal separation ranged from 500 to 5000. End point 
titers of immunoblot reactivity of sera EBA13 and EBA14, that were not able to 
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Figure 5. Serum from an EBA patient recruits neutrophils to the dermal-epidermal 
junction and induces subepidermal splits. (a) Cryosections of normal human skin, 
incubated with EBA serum, show IgG deposits at the dermal-epidermal junction by indirect 
IF microscopy. (b) Subsequent addition of leukocytes leads to neutrophil recruitment to the 
dermal-epidermal junction. (c) Activation of neutrophils, as revealed by reduction of NBT to 
formazan (dark precipitates), is induced by EBA serum, (d) but not by normal human 
serum. (e) With longer incubation times, subepidermal splits develop in the cryosection 
that were treated with EBA serum. (f) In contrast, serum from a healthy donor does not 
induce neutrophil recruitment or dermal-epidermal separation. Bar, 40 µm.
induce separation, were 1000 and 2000, respectively. To address the question if the 
addition of complement augments the extent of dermal-epidermal separation in this 
model, we incubated cryosections, that were previously treated with EBA sera, with 
1) leukocytes and fresh serum, 2) leukocytes and complement-inactivated (heated) 
serum, or 3) with leukocytes alone. Interestingly, the addition of complement did not 
increase the extent of dermal-epidermal separation in the cryosections compared 
with the extent observed when complement was heat-inactivated or omitted 
completely. In the presence of complement we observed neutrophil attachment to 
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Figure 6. Granulocytes, but not 
mononuclear cells, are required for split 
induction by autoantibodies from EBA 
patients in cryosections of human skin. 
(a) Granulocytes,  that were isolated from 
the blood of healthy donors, mediate 
subepidermal cleavage in cryosections 
treated with an EBA serum. (b) In contrast, 
mononuclear cells are not recruited to the 
DEJ and do not cause subepidermal 
cleavage.
the stratum corneum in all cryosections irrespective of whether they were incubated 
with serum from patients or controls. Since complement did not play a role in this 
model, further experiments did not include fresh serum as a source of complement. 
Leukocytes at the Dermal-Epidermal Junction are Activated
To determine if leukocytes that attach to the DEJ become activated, we incubated 
cryosections, that had been treated with patients’ sera (EBA3, EBA10, and EBA16), 
with leukocytes in the presence of NBT. After a 30 minute incubation, dark blue 
precipitates of reduced NBT (formazan) were found at both DEJ and stratum 
corneum (Figure 5c). In sections treated with normal human serum, no recruitment 
of cells to the DEJ was observed and blue precipitates were restricted to the stratum 
corneum (Figure 5d). 
Granulocytes, but not Mononuclear Cells, are Required for Split Formation 
Induced by Autoantibodies from EBA Patients in Cryosections of Human Skin
To dissect the role of different leukocyte subpopulations in the split-formation 
induced by EBA autoantibodies, granulocytes and peripheral blood mononuclear 
cells from healthy donors were separated by gradient centrifugation. The 
preparations were used at a density of 3 x 107 cells/ml. When incubated with the 
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cryosections that had been treated with serum from EBA3, EBA10, and EBA16, only 
granulocytes (Figure 6a), but not mononuclear cells (Figure 6b), were recruited to 
the dermal-epidermal junction and induced subepidermal splits.
The Cleavage Plane of Experimentally Induced Splits Localizes to the Lamina 
Lucida Zone of the Dermal-Epidermal Junction
To study the level of split formation, we stained cryosections, that had previously 
been incubated with sera from EBA patients and leukocytes, with monoclonal 
antibodies to human BP230 (1E5), type IV collagen, and laminin 5. Antibodies to 
BP230 stained the roof of the split, whereas those to both type IV collagen and 
laminin 5 labeled the dermal side demonstrating that the level of blister formation 
localizes to the lamina lucida of the DEJ (Figure 7).
IgG Purified from Serum of EBA Patients Retains its Blister-Inducing Ability 
To confirm the results obtained with patients’ sera, we purified the IgG fractions of 5 
EBA sera by Protein G column chromatography (Table 2). IgG preparations from 
patients and controls were used at the same IgG concentration. When incubated 
with the cryosections, IgG from EBA patients, in contrast to IgG from controls, 
induced subepidermal splits. 
Figure 7. By antigen mapping, experimentally induced splits localise to the lamina 
lucida of the dermal-epidermal junction. Cryosections, that had been previously 
incubated with EBA sera and leukocytes, were stained with monoclonal antibodies to 
BP230 and laminin 5. Monoclonal antibody E5 to BP230 bound to the epidermal side of the 
cleft (a), whereas GB3 antibody to laminin 5 stained the dermal side (b) demonstrating that 
skin cleavage localizes to the lamina lucida zone of dermal-epidermal junction. Scale bar: 
40 µm.
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Table 2. Characterization of affinity-purified IgG preparationsA
Patient ConcentrationB
(mg/ml)
IIF Titerc Type VII collagenD rNC1E
EBA4 22.5 160 + +
EBA5 17.5 80 + +
EBA7 25 320 + +
EBA8 62.5 640 + +
EBA11 21.3 160 + +
ATotal IgG fractions were isolated from human sera using protein G affinity column 
chromatography. BConcentrations of affinity-purified IgG was determined using 
absorbance at 280 nm. cAntibody titer by indirect IF microscopy on 1M NaCl-split 
human skin. DImmunoblot reactivity with full-lenght type VII collagen extracted from 
dermis. EImmunoblot reactivity with the recombinant NC1 domain of type VII 
collagen.
Antibodies Specific to the NC1 Domain of Type VII Collagen Induce 
Subepidermal Cleavage in Cryosections of Human Skin 
In order to characterize the specificity of pathogenic autoantibodies from EBA sera, 
we purified antibodies from 5 EBA patients against a recombinant form of type VII 
collagen. Total IgG from the flow-through fractions was further purified by Protein G 
column chromatography. The reactivity and specificity of antibodies eluted from NC1 
coupled to agarose and of IgG purified from the flow-through fractions are 
summarized in Table 3 and representative patterns are shown in Figure 8. 
Importantly, when incubated with the cryosections, eluted autoantibodies specific to 
type VII collagen induced subepidermal splits ( Figure 8Ca), whereas IgG depleted of 
reactivity to the NC1 domain of type VII collagen lost its blister-inducing ability 
(Figure 8Cb). 
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Table 3. Characterization of immunoaffinity-purified immunoglobulin 
preparations 
Patient IgG Preparation ConcentrationC
(mg/ml)
IIF 
TiterD
Type VII 
collagenE
rNC1F
Purification against recombinant NC1 encoded by BV-NC1A
EBA4 Eluted fraction 2.7 320 + 2000G
Flow-through fraction 21 - - -
EBA5 Eluted fraction 0.68 160 + 2000G
Flow-through fraction 3.72 - - -
EBA6 Eluted fraction 2.56 160 + 2000G
Flow-through fraction 2.2 - - -
EBA7 Eluted fraction 2.81 160 + 1000G
Flow-through fraction 2.11 - - -
EBA8 Eluted fraction 0.68 320 + 5000G
Flow-through fraction 39 - - -
Purification against the vector-specific peptide encoded by BV-0 B
EBA 7 Eluted fraction 0.01 - N.D. -
Flow-through fraction 10 320 N.D. +
EBA8 Eluted fraction 0 - N.D. -
Flow-through fraction 12 160 N.D. +
EBA11 Eluted fraction 0.009 - N.D. -
Flow-through fraction 8 160 N.D. +
AAntibodies to type VII collagen from patients‘ sera were purified against 
recombinant NC1 covalently coupled to an agarose matrix. B Patients‘ sera were 
purified against Ni-NTA-purified lysate of Sf21 insect cells infected with BV-0. 
CConcentrations of affinity-purified antibodies were determined using absorbance at 
280 nm. DAntibody titer by indirect IF microscopy on 1M NaCl-split human skin. 
EImmunoblot reactivity with full-lenght type VII collagen extracted from dermis. 
FImmunoblot reactivity with the recombinant NC1 domain of type VII collagen. GEnd 
point titers of immunoblot reactivity with recombinant NC1.
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Figure 8. Immunoadsorption of EBA serum against the recombinant NC1 domain of 
type VII collagen abolishes split induction. Autoantibodies to type VII collagen from EBA 
serum were purified using a recombinant form of the NC1 domain covalently coupled to an 
agarose matrix. (A) When analyzed by indirect IF microscopy (a) IgG eluted from 
recombinant NC1 retains reactivity with the dermal side of NaCl-split human skin, (b) in 
contrast to IgG from the flow-through fraction that completely lost IF reactivity. (B) By 
immunoblotting, IgG autoantibodies eluted from the column (lane 3) recognized, like a serum 
sample from the same patient (lane 1) both full-lenght type VII collagen  extracted from 
dermis (arrow) and a recombinant form of its NC1 domain (arrowhead). In contrast, the flow-
through fraction (lane 2) or normal serum (lane 4) showed no reactivity. (C) When incubated 
with the cryosections, (a) the patient’s autoantibodies specific to type VII collagen NC-1, 
induce dermal-epidermal separation, (b) while IgG depleted of reactivity to the NC1 domain 
(flow-through fraction) does not . Bar, 40 µm.
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Figure 9. Preadsorption of EBA serum against proteins from insect cells infected with 
recombinant BV-0, lacking NC1-cDNA, does not abolish its blister-inducing capacity. 
EBA serum was purified against proteins from insect cells infected with recombinant BV-0 
coupled to an agarose matrix. (A) By indirect IF microscopy, (a) IgG eluted from the column 
that completely lost indirect IF reactivity, (b) in contrast IgG from the flow-through fraction 
stained the dermal side of salt-split skin. (B) By immunoblotting, like the original serum (lane 
1), the flow-through fraction (lane 2), reacted with recombinant NC1, while the eluted fraction 
(lane 3), like normal human serum (lane 4), was unreactive. (C) When incubated with 
cyosections, (a) in contrast to the eluted fraction, (b) the flow-through fraction retained its 
ability to induce blisters. Bar, 40 µm.
To exclude the possibility that baculovirus- or insect cell-specific proteins other than 
recombinant NC1 non-specifically pre-adsorb the blister-inducing capacity of EBA 
sera, we purified 3 sera (EBA7, EBA8, and EBA11) against the recombinant vector-
specific peptide, encoded by BV-0, not containing any NC1 sequence. Eluted 
fractions of this purification were non-reactive by indirect IF microscopy on salt-split 
skin and by immunoblotting with recombinant NC1 (Figure 9Aa, B lane 3), whereas 
IgG from the flow-through (preadsorbed serum) stained the dermal side of salt-split 
skin by indirect IF microscopy (Table 3, Figure 9Ab) and reacted with recombinant 
NC1 by immunoblotting (Figure 9B, lane 2). Both eluted and flow-through fractions 
were then incubated with the cryosections followed by incubation with leukocytes. 
Eluted fractions did not cause subepidermal splits, in contrast to flow-though 
fractions that were still pathogenic (Figure 9C). These results demonstrate that 
immunoadsorption of type VII collagen-specific antibodies was only achieved with 
recombinant NC1, but not with other proteins produced by baculovirus-infected 
insect cells.
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Autoantibodies to Type VII Collagen Induce a Dose-Dependent Dermal-
Epidermal Separation in The Cryosections 
To study the dependency of the extent of split formation on autoantibody reactivity to 
type VII collagen, we incubated the cryosections with different dilutions of both EBA 
sera and immunoaffinity-purified antibody preparations followed by incubation with 
leukocytes. As shown in Table 4, EBA sera and NC1-specific antibody preparations 
with higher indirect IF titers induced more extensive DEJ separation compared with 
preparations of lesser reactivity.
Table 4. Serum samples and NC1-specific autoantibodies from EBA patients 
induce a dose-dependent dermal-epidermal separation in cryosections of 
human skin
EBA sera NC1-specific antibody preparationsA
Patient Dilution IIF 
TiterB
DES 
(%)C
Patient Dilution IIF 
TiterB
DES 
(%)C
EBA8 1:2 80 70 EBA8 1:4 80 65
1:4 40 60 1:16 20 40
1:16 10 40 1:64 5 5
1:160 1 10 1:320 1 0
EBA11 1:4 80 60 EBA11 1:2 80 75
1:8 40 55 1:8 20 50
1:32 10 30 1:32 5 30
1:320 1 5 1:160 1 10
AAntibodies specific to NC1 were purified from the serum of 2 EBA patients by 
immunoaffinity column chromatography and incubated with cryosections of human 
skin followed by a 2 h incubation with human leukocytes. BTiter of antibodies by 
indirect IF microscopy on 1M NaCl-split human skin. CLength of DEJ with separation 
in relation to total length (percent).
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A Monoclonal Antibody to the NC1 Domain of Type VII Collagen Induces 
Subepidermal Splits in the Cryosections 
MAb LH7.2, directed to an epitope on the central portion of the NC1 domain of type 
VII collagen induced dermal-epidermal separation of the cryosections (Figure 10a). 
In contrast, a mAb to type IV collagen, that belonged to the same isotype and was 
used at the same IgG concentration (0.1 mg/ml), was not pathogenic (Figure 10b). 
The extent of split formation induced by mAb LH7.2 was less pronounced when 
compared with patients’ autoantibodies to type VII collagen and split-induction 
required a longer incubation time with leukocytes (3 h). 
F(ab’)2 Fragments of Blister-Inducing Autoantibodies Lose their Pathogenicity
To address the question, if the Fc portion of autoantibodies to type VII collagen is of 
importance for blister induction in our in vitro model, we prepared F(ab‘)2 fragments 
of antibodies from EBA serum that had been eluted from recombinant NC1 coupled 
to agarose. F(ab‘)2 fragments, lacking the Fc portion of the antibody, labeled the 
dermal side of NaCl-split skin by indirect IF microscopy (Figure 11a, b). Interestingly, 
F(ab‘)2 preparations, although used at the same indirect IF titer (80) as unfragmented 
Figure 10. A mAb to the NC1 domain of 
type VII collagen induces subepidermal 
splits in cryosections of human skin. (a) 
Incubation of cryosections with mAb LH7.2, 
directed to the NC1 domain, and 
subsequently with leukocytes leads to dermal-
epidermal separation, (b) in contrast to a mAb 
to type IV collagen that was used at the same 
IgG concentration. * Asterisk indicates the 
cleavage. Bar, 40 µm.
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IgG, failed to recruit neutrophils to the DEJ and to induce subepidermal cleavage 
when incubated with the cryosections (Figure 11c, d).
Figure 11. Dermal-epidermal separation is dependent on the Fc portion of 
autoantibodies to type VII collagen. Patient’s autoantibodies, that had been purified 
against recombinant NC1 of type VII collagen, were subsequently subjected to pepsin 
digestion. (a) Resulting F(ab’)2 fragments labeled the dermal side of 1M NaCl-split skin by 
indirect IF microscopy using an anti-Fab FITC-conjugated secondary antibody, (b) whereas 
no staining was observed using a an Fc-specific conjugate. (c) F(ab’)2 fragments failed to 
induce blisters, (d) in contrast to unfragmented autoantibodies to type VII collagen. 
Bar, 40 µm.
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Discussion
In this study, we show the capacity of autoantibodies to type VII collagen from EBA 
patients and of a monoclonal antibody to this protein to trigger an Fc-dependent  
inflammation leading to blister formation in cryosections of human skin. The
pathogenicity of autoantibodies from patients with autoimmune blistering diseases 
directed to several structural components of the skin, including type XVII collagen, 
64 integrin, and laminin 5 had been previously demonstrated. In contrast, previous 
attempts to induce EBA by passive transfer of patients‘ autoantibodies into neonatal 
mice (Shigemoto et al, 1988; Borradori et al, 1995) or human skin grafted onto SCID 
mice had failed (Chen et al, 1992).
In a first set of experiments, we show that serum from EBA patients, in contrast to 
serum from healthy donors, induces recruitment and activation of neutrophils at the 
DEJ of the cryosections and, subsequently, dermal-epidermal separation. The 
development of subepidermal cleavage in cryosections, that strongly adhere to the 
glass slide, might be due to a “natural tension” within the DEJ. Indeed, bundles of 
elastic microfibrils of the lamina fibroreticularis anchor the basal lamina to dermal 
elastic fibres (Kobayashi 1977). Cleavage of components of the anchoring 
complexes by leukocyte-derived proteases may release this tension resulting in a 
recoil of elastic fibres and retraction of the dermis from the epidermis. 
Complement was not required for split induction in this model. The group of EBA 
patients included in the present study was heterogeneous with respect to the 
complement-activation capacity of their serum. Serum from 5 of 16 patients did not 
fix complement to the dermal-epidermal junction as detected by indirect IF 
microscopy, in contrast to the remaining EBA sera. When complement was heat-
inactivated or ommited completely, this did not affect the split induction by EBA sera 
in our in vitro assay. These observations confirm previous findings (Gammon and 
Briggaman 1987; Mooney and Gammon 1990; Gandhi et al, 2000) and suggest that 
complement activation is not likely to play a major pathogenic role in the blister 
formation at least in a subgroup of patients with EBA. However, in the cryosection 
model, in contrast to the in vivo situation, the leukocytes do not have to migrate 
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along a chemotactic gradient from blood vessels to the DEJ. Instead, by incubating 
the cryosections with leukocytes, the cells are placed in close contact with the DEJ. 
Therefore, the role of complement in the blister formation in EBA patients cannot be 
addressed using this model.
When fresh serum was added as a source of complement, we regularly found strong 
attachment of neutrophils to the stratum corneum of the cryosections, irrespective of 
whether the sections were incubated with serum from patients or controls. This 
observation, that we also made in previous studies using this in vitro assay (Sitaru et 
al, 2002), is in line with the finding that corneocytes may activate the alternative 
complement pathway thus mediating the adhesion of leukocytes to serum-treated 
stratum corneum in an antibody-independent manner (Terui et al, 1989; Terui et al,
1995). When fresh serum was ommited or replaced by heat-inactivated serum, we 
did not observe a major neutrophil adhesion to stratum corneum.
Of the 16 EBA sera we tested, 2 did not induce a split. Interestingly these sera came 
from 2 children and showed high reactivity by both indirect IF microscopy and 
immunoblotting of recombinant NC1. One may speculate that in these 2 patients, 
another pathogenic mechanism accounts for blister formation, which, in contrast to 
the majority of EBA sera, cannot be reproduced in our in vitro model. 
In subsequent experiments, our findings with crude EBA serum were confirmed with 
the use of IgG purified from patients‘ sera. In contrast to IgG from healthy controls, 
patients’ IgG, when used at the same concentration, caused dermal-epidermal 
separation in the cryosections. 
In the next set of our experiments we sought to determine the ultrastructural level of 
experimentally induced splits by antigen mapping. Interestingly, we found that the 
cleavage plane localizes to the lamina lucida of the DEJ. It has been previously 
shown that the level of blister formation does not always co-localize with the site of 
deposition of immunoreactants, for example in patients with dermatitis herpetiformis 
(Klein et al, 1983; Smith et al, 1992). The lamina lucida was viewed as a mechanical 
“locus minoris resistentiae” of the DEJ. The first electron microscopic studies of EBA 
patients, that belonged to the classical type of EBA, indicated the sublamina densa 
as the level of blister formation (Gibbs and Minus 1975); subsequent observations 
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showed that in the majority of the EBA patients the cleavage plane occurs within the 
lamina lucida also showing some correlation with the presence of neutrophil 
infiltration (Fine et al, 1989; Honoki et al, 1998). Double sublamina densa and lamina 
lucida localized split was also documented in one patient (Fine et al, 1989). These 
observations support the involvement of two different pathogenic mechanisms of 
blister formation in EBA that may act independently or occasionally in combination. 
By binding to type VII collagen, EBA autoantibodies, on one hand, may disrupt the 
interaction of type VII collagen with fibronectin or may interfere with the antiparallel 
dimer formation leading to blister formation within the sublamina densa. On the other 
hand, the formed IC may mediate recruitment and activation of neutrophils leading to 
a release of proteases and blister formation within the lamina lucida of the DEJ. Most 
likely, the level of cleavage within the sublamina densa may correlate with scarring 
and milia formation as typically seen in mechano-bullous form of EBA, while intra-
lamina lucida blister formation may be found in blisters not associated with scarring 
and milia as seen in the inflammatory form of EBA. However, these 2 variants of 
EBA may represent only ends of a continuous spectrum and the individual clinical 
features may be determined by the different involvement of these two mechanisms.
Sufficient clinical data was available for 14 out of 16 patients included in the present 
study to diagnose these as non-inflammatory or inflammatory EBA. Nine belonged to 
the non-inflammatory and the remaining 5 patients to the inflammatory type. Serum 
from all nine non-inflammatory patients and from 3 patients with inflammatory 
disease caused dermal-epidermal separation in the cryosections. Further studies, 
based on a larger number of patients, will have to show if serum from non-
inflammatory patients really have a greater split-inducing potential compared to 
serum from patients with inflammatory EBA.
The NC1 domain has been characterised as the immunodominant region of type VII 
collagen that is targeted by the majority of EBA sera (Gammon et al, 1993; Lapiere
et al, 1993; Tanaka et al, 1994; Chen et al, 2001). To characterise the specificity of 
split-inducing autoantibodies in these sera, we produced a recombinant form of the 
NC1 domain expressed in baculovirus-infected insect cells. After purification by 
metalochelate affinity chromatography, the recombinant protein was used for 
immunoblotting with a monoclonal antibody to type VII collagen as well as serum 
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samples from patients with EBA, with other autoimmune bullous diseases and from 
healthy controls. Autoantibodies from serum of EBA patients were purified against 
recombinant NC1 that was covalently coupled to an agarose matrix. Importantly, 
antibodies eluted from the NC1 column retained their blister-inducing capacity, while 
IgG that was depleted of reactivity to NC1 lost its ability to recruit neutrophils and to 
induce blisters. To exclude the possibility that proteins produced by baculovirus-
infected insect cells others than recombinant NC1 were responsible for pre-
adsorbing the blister-inducing capacity of EBA sera, we purified serum from EBA 
patients against the recombinant vector-specific peptide, encoded by BV-0, not 
containing any NC1 sequence. These pre-adsorbed fractions retained the blister-
inducing ability of original EBA sera demonstrating that the pre-adsorption procedure 
was antigen-specific.
In the next set of experiments we studied the dependency of the extent of dermal-
epidermal separation on autoantibody reactivity to type VII collagen. We show that 
EBA sera and NC1-specific antibody preparations with higher indirect IF titers 
induced more extensive DEJ separation compared with preparations with lesser 
reactivity. This finding suggests that clinical activity of the disease (i.e., the extent of 
skin blistering) may correlate with the levels of autoantibody reactivity to type VII 
collagen in serum of patients with EBA.
The pathogenic relevance of the NC1 region was further supported by the finding 
that mAb LH7.2, directed to an epitope on the central portion of the NC1 domain of 
type VII collagen, in contrast to a mAb to type IV collagen, also induced 
subepidermal splits of the cryosections. The extent of splits caused by mAb LH7.2 
was less pronounced than splits in sections incubated with patients’ sera. This may 
be due to the fact that, in contrast to patients’ autoantibodies, LH7.2 is directed to a 
single epitope on type VII collagen. Recently, it was reported that the blister-inducing 
capacity of mAbs to the ectodomain of type XVII collagen/BP180, a major target of 
autoantibodies in bullous pemphigoid patients, was enhanced when 2 mAbs were 
concurrently injected into human skin grafted onto athymic mice compared with the 
single use of these mAbs (Egan et al, 1999). These and our own results suggest that 
the extent of split formation may be increased when antibodies target different 
epitopes on the same autoantigen. In addition, mouse IgG1 may have a weaker 
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affinity for Fc receptors expressed on human neutrophils in comparison with human 
IgG. This may lead to less neutrophil adhesion to the DEJ and subsequently to a 
lesser dermal-epidermal separation by mouse monoclonal IgG1 antibody when 
compared with autoantibodies from EBA patients.
In a further set of experiments, we studied the importance of leukocytes for dermal-
epidermal separation in this model. With shorter incubation times (30 to 90 minutes), 
recruitment of leukocytes to the DEJ predominated over the induction of a cleavage, 
whereas the extent of dermal-epidermal separation gradually increased with longer 
incubation and reached its maximum after an incubation of 2 h. By two independent 
lines of evidence we demonstrate that dermal-epidermal separation of the 
cryosections, induced by autoantibodies to type VII collagen, is dependent on the 
presence of leukocytes: i) omitting leukocytes abolished the induction of 
subepidermal splits; ii) in contrast to undigested antibodies, their F(ab’)2 fragments, 
that lacked the effector (Fc) portion, lost the blister-inducing ability when incubated 
with the cryosections. Leukocytes at the DEJ were activated, as demonstrated by 
their ability to generate a respiratory burst. In contrast to granulocytes, preparations 
of mononuclear cells were not able to mediate subepidermal cleavage. 
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Conclusion
This study demonstrates that antibodies to the NC1 domain of type VII collagen 
mediate an Fc-dependent neutrophil activation and induce dermal-epidermal 
separation in cryosections of human skin. Future studies will be aimed at 
characterising the factors that determine the blister-inducing potential of 
autoantibodies to type VII collagen, especially the pathogenically relevant IgG 
subclasses and their interaction with Fc receptors expressed on leukocytes. In 
addition, this experimental model may eventually contribute to the development of 
novel therapeutic strategies for this disease.
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Summary
Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering 
disease associated with autoantibodies to type VII collagen, the major constituent of 
anchoring fibrils. Previous attempts to demonstrate the blister inducing potential of 
autoantibodies to this protein have failed. To address this question, we used an in 
vitro model involving cryosections of human skin incubated with patients’ 
autoantibodies and leukocytes from healthy donors. We show that sera from 14 out 
of 16 EBA patients, in contrast to sera from healthy controls, induced dermal-
epidermal separation in the cryosections. The level of the experimentally induced 
split localizes to the lamina lucida of the dermal-epidermal junction. Recruitment and 
activation of neutrophils at the dermal-epidermal junction was necessary for split 
induction, whereas mononuclear cells were not required. Importantly, patients’ 
autoantibodies affinity-purified against a recombinant form of the non-collagenous 1 
(NC1) domain of type VII collagen retained their blister-inducing capacity, while 
patients’ IgG that was depleted of reactivity to type VII collagen lost this ability. 
Monoclonal antibody LH7.2 to the NC1 domain of type VII collagen also induced 
subepidermal splits in the cryosections; F(ab’)2 fragments of autoantibodies to type 
VII collagen were not pathogenic. These findings demonstrate the capacity of 
autoantibodies to type VII collagen to trigger an Fc-dependent inflammation leading 
to split formation in cryosections of human skin.
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Zusammenfassung
Die Epidermolysis bullosa acquisita (EBA) ist eine subepidermal blasenbildende 
Autoimmundermatose, die mit Autoantikörpern gegen Typ VII Kollagen, den 
Hauptbestandteil der Verankerungsfibrillen der dermo-epidermalen Junktionszone 
(DEJ), assoziert ist. Bislang war jedoch unklar, ob diese Autoantikörper tatsächlich 
eine Blasenbildung verursachen. In der vorliegenden Arbeit gingen wir dieser Frage 
unter Verwendung eines Gefrierschnitt-Modells nach. Nach Koinkubation mit 
Leukozyten gesunder Spender induzierten 14 von 16 EBA-Seren eine 
subepidermale Spaltbildung, nicht jedoch die Seren von gesunden Freiwilligen. Die 
Spaltbildung erfolgte im Bereich der Lamina lucida der DEJ und war von der 
Rekrutierung und Aktivierung neutrophiler Granulozyten, nicht jedoch von der 
Präsenz mononuklearer Zellen abhängig. Autoantikörper von Patienten, die gegen 
eine rekombinante Form der NC1-Domäne des Typ VII Kollagens 
affinitätsaufgereinigt wurden, und der gegen die NC-1-Domäne gerichtete 
monoklonale Antikörper LH7.2 induzierten ebenfalls eine subepidermale Spaltildung. 
Dagegen führte die Präadsorption der EBA-Seren mit rekombinantem Typ VII 
Kollagen zum Verlust des blaseninduzierenden Potentials. Diese Fähigkeit verloren 
auch durch Pepsinverdau hergestellte F(ab’)2-Fragmente der Patienten-
Autoantikörper gegen Typ VII Kollagen. Die Ergebnisse dieser Arbeit zeigen, dass 
Autoantikörper gegen Typ VII Kollagen eine Fc-abhängige Entzündung und 
subepidermale Spaltbildung in Gefrierschnitten humaner Haut hervorrufen.
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